PRLH Inhibitors
Chemical inhibitors of PRLH function primarily by disrupting the critical signaling pathways upon which PRLH relies for its activity. Wortmannin and LY294002 are two such inhibitors that target phosphoinositide 3-kinase (PI3K), a pivotal enzyme in the PRLH signaling cascade. By inhibiting PI3K, these chemicals reduce the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a lipid second messenger crucial for the activation of downstream effectors in the PRLH pathway. This action effectively diminishes the functional activity of PRLH. Similarly, the compounds Rapamycin and PP242 exert their inhibitory effects by targeting the mammalian target of rapamycin (mTOR), a kinase that is part of the broader PI3K/Akt/mTOR pathway. By inhibiting mTOR, these substances indirectly impact PRLH activity, as the mTOR pathway is integrally related to the functional output of PRLH signaling.
Further down the PRLH signaling pathway, PD98059 and U0126 serve as selective inhibitors of mitogen-activated protein kinase kinase (MEK), which is upstream of the extracellular signal-regulated kinase (ERK). By preventing MEK from activating ERK, these inhibitors indirectly suppress PRLH activity. In a related mechanism, SB203580 targets p38 MAPK, another kinase that is associated with PRLH signaling, while SP600125 inhibits the c-Jun N-terminal kinase (JNK), further demonstrating the diversity of kinases that can be modulated to influence PRLH activity. Moreover, PI-103 and ZSTK474 are effective in inhibiting PRLH function by suppressing both PI3K and mTOR pathways, thereby demonstrating a multipronged approach to inhibiting the signaling pathways associated with PRLH. Finally, Torin 1 and PF-04691502, which are dual inhibitors of PI3K and mTOR, comprehensively block the activation of pathways necessary for PRLH signaling, ensuring the downregulation of PRLH's functional activity. These chemical inhibitors, by acting on various kinases involved in PRLH signaling, collectively contribute to the modulation of PRLH activity without directly interacting with the protein itself.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. PRLH signaling relies on the downstream effects of PI3K activity. By inhibiting PI3K, wortmannin can reduce the functional activity of PRLH as PI3K is necessary for the full activation of pathways that PRLH is part of. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar in function to Wortmannin. It inhibits PI3K, leading to a decrease in the phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels in cells, thus inhibiting the pathways that are required for PRLH to exert its effects. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTOR pathway, which is connected to the PI3K/Akt pathway, a pathway necessary for PRLH function. By inhibiting mTOR, Rapamycin indirectly reduces PRLH activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can decrease ERK phosphorylation, indirectly inhibiting PRLH signaling that relies on this pathway for full activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK kinase, leading to an inhibition of the ERK signaling pathway. As ERK signaling is necessary for PRLH activity, U0126 can thus indirectly inhibit PRLH function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a protein kinase involved in the response to stress and cytokines. PRLH activity is linked to the pathways governed by p38 MAPK, and inhibition by SB203580 can therefore indirectly inhibit PRLH. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the c-Jun N-terminal kinase (JNK), which is involved in a multitude of cellular processes including those that regulate PRLH. Inhibition of JNK by SP600125 can result in reduced PRLH activity. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective mTOR kinase inhibitor, more potent and selective than Rapamycin. It inhibits both mTORC1 and mTORC2 complexes, which play roles in PI3K/Akt signaling, indirectly inhibiting PRLH function. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a potent, synthetic molecule that inhibits PI3K and mTOR, which are part of the signaling pathways PRLH relies on. By inhibiting these kinases, PI-103 can decrease PRLH functional activity. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 inhibits PI3K, leading to the suppression of the downstream Akt signaling pathway. This suppression can indirectly inhibit the function of PRLH, which relies on the integrity of this pathway. | ||||||